Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
α-SC9
- Development stage
- Preclinical
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
α-SC9 is an experimental recombinant protein vaccine candidate designed for the treatment of synucleinopathies, including Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Developed using a rational design approach, the vaccine utilizes the prion domain of the fungal HET-s protein as a rigid structural scaffold. Specific epitopes from the surface of alpha-synuclein amyloid fibrils are grafted onto this scaffold to mimic the parallel in-register beta-sheet structure characteristic of pathological aggregates. This design allows the immune system to generate high-affinity IgG antibodies that selectively recognize and target misfolded alpha-synuclein fibrils while avoiding cross-reactivity with native, monomeric alpha-synuclein, thereby reducing the risk of harmful autoimmune responses.
- Other names
- alpha-SC9alpha-SC-9alpha-SC 9
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on α-SC9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on α-SC9.